Back to Search Start Over

A health technology assessment of personalized nutrition interventions using the EUnetHTA HTA Core Model.

Authors :
Galekop MMJ
Del Bas JM
Calder PC
Uyl-De Groot CA
Redekop WK
Source :
International journal of technology assessment in health care [Int J Technol Assess Health Care] 2024 Mar 06; Vol. 40 (1), pp. e15. Date of Electronic Publication: 2024 Mar 06.
Publication Year :
2024

Abstract

Objectives: Poor nutrition links to chronic diseases, emphasizing the need for optimized diets. The EU-funded project PREVENTOMICS, introduced personalized nutrition to address this. This study aims to perform a health technology assessment (HTA) comparing personalized nutrition interventions developed through this project, with non-personalized nutrition interventions (control) for people with normal weight, overweight, or obesity. The goal is to support decisions about further development and implementation of personalized nutrition.<br />Methods: The PREVENTOMICS interventions were evaluated using the European Network for HTA Core Model, which includes a methodological framework that encompasses different domains for value assessment. Information was gathered via [1] different statistical analyses and modeling studies, [2] questions asked of project partners and, [3] other (un)published materials.<br />Results: Clinical trials of PREVENTOMICS interventions demonstrated different body mass index changes compared to control; differences ranged from -0.80 to 0.20 kg/m <superscript>2</superscript> . Long-term outcome predictions showed generally improved health outcomes for the interventions; some appeared cost-effective (e.g., interventions in UK). Ethical concerns around health inequality and the lack of specific legal regulations for personalized nutrition interventions were identified. Choice modeling studies indicated openness to personalized nutrition interventions; decisions were primarily affected by intervention's price.<br />Conclusions: PREVENTOMICS clinical trials have shown promising effectiveness with no major safety concerns, although uncertainties about effectiveness exist due to small samples (n=60-264) and short follow-ups (10-16 weeks). Larger, longer trials are needed for robust evidence before implementation could be considered. Among other considerations, developers should explore financing options and collaborate with policymakers to prevent exclusion of specific groups due to information shortages.

Details

Language :
English
ISSN :
1471-6348
Volume :
40
Issue :
1
Database :
MEDLINE
Journal :
International journal of technology assessment in health care
Publication Type :
Academic Journal
Accession number :
38444327
Full Text :
https://doi.org/10.1017/S0266462324000060